The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma

References

• Horning JS. Risk, cure and complications in advanced Hodgkin disease. Hematology Am Soc Hematol Educ Program 2007:197–203.
   PubMedGoogle Scholar
• Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478–1484.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. N Engl J Med 1998;339:1506–1514.
   PubMed Web of Science ®Google Scholar
• Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med 2010;362:875–885.
   PubMed Web of Science ®Google Scholar
• Zender T, Wiedenmann S, Wolf J. Prognostic factors in Hodgkin’s lymphoma. Ann Oncol 2002;13:67–74.
   PubMed Web of Science ®Google Scholar
• Ferme C, Bastion Y, Brice P, et al. Prognosis of patients with advanced Hodgkin’s disease: evaluation of prognosis of four prognostic models using 344 patients included in the Group D’Etudes des Lymphomes de l’Adulte Study. Cancer 1997;80:1124–1133.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, et al. Prognostic factors in advanced stage Hodgkin’s lymphoma: the significance of the number of involved anatomic sites. Eur J Haematol 2001;67:279–288.
   PubMed Web of Science ®Google Scholar
• Gobbi PG, Zinzani PL, Broglia C, et al. Comparsion of prognostic models in patients with advanced Hodgkin’s disease: promising results from integration of the best three systems. Cancer 2001;91:1467–1478.
   PubMed Web of Science ®Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Costwold meeting. J Clin Oncol 1989;7:1630–1636.
   PubMed Web of Science ®Google Scholar
• Von Wasielewski R, von Wasielewski S, Franklin P, et al. Nodular sclerosing HD: a new proposal to distinguish high-risk patients. Leuk Lymphoma 2001;42(Suppl. 2):82.
   Google Scholar
• Sup SJ, Alemany CA, Pohlman B, et al. Expression of Bcl-2 in classical Hodgkin’s lymphoma: an independent predictor of poor outcome. J Clin Oncol 2005;23:3773–3779.
   PubMed Web of Science ®Google Scholar
• Alvaro-Naranjo T, Leujeune M, Salvado-Usach MT, et al. Tumor infiltrating cells as prognostic factor in Hodgkin’s lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma 2005;46:1581–1591.
   PubMed Web of Science ®Google Scholar
• Kelley TW, Pohlman B, Elson P, Hsi ED. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 2007;128:958–965.
   PubMed Web of Science ®Google Scholar
• Specht L. Tumour burden as the main indicator of prognosis in Hodgkin’s disease. Eur J Cancer 1992;28A:1982–1985.
   Google Scholar
• Anderson H, Jenkins JP, Brigg DJ, et al. The prognostic significance of mediastinal bulk in patients with stage IA-IVB Hodgkin’s disease: a report from a report from the Manchester Lymphoma Group. Clin Radiol 1985;36:449–454.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoetic and lymphoid tissues. 4th ed. Lyon:International Agency for Research on Cancer; 2008.
   Google Scholar
• Diehl V, Thomas RK, Re D. Part II: Hodgkin’s lymphoma-diagnosis and treatment. Lancet Oncol 2004;5:19–26.
   PubMed Web of Science ®Google Scholar
• Juszczynski P, Ouyang J, Monti S, et al. The AP1-dependent secretion of galectin-1 by Reed-Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA 2007;104:13134–13139.
   PubMed Web of Science ®Google Scholar
• Lamprecht B, Kreher S, Anagnostopoulos I, et al. Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3α. Blood 2008;112:3339–3347.
   PubMed Web of Science ®Google Scholar
• Pinto A, Aldinucci D, Gloghini A, et al. The role of eosinophils in the pathobiology of Hodgkin’s disease. Ann Oncol 1997;8:89–96.
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Gattei V, et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin’s disease cell lines. Blood 1995;85:780–789.
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Lorenzon D, Olivo K, Rapana B, Gattei V. Interactions between tissue fibroblasts in lymph nodes and Hodgkin/Reed-Sternberg cells. Leuk Lymphoma 2004;45:1731–1739.
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Olivo K, Lorenzon D, et al. The role of interleukin-3 in classical Hodgkin’s disease. Leuk Lymphoma 2005;46:303–311.
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Lorenzon D, Cattaruzza L, et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/RANTES in tumour cell growth and microenvironmental interactions. Int J Cancer 2008;122:769–776.
   PubMed Web of Science ®Google Scholar
• Cattaruzza L, Gloghini A, Olivo K, et al. Functional coexpression of interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: involvement of IL-7 in tumour cell growth and microenvironmental interactions of Hodgkin’s lymphoma. Int J Cancer 2009;125:1092–1101.
   PubMed Web of Science ®Google Scholar
• Buri C, Korner M, Scharli P, et al. CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the non-neoplastic leukocytic infiltrates of Hodgkin disease. Blood 2001;97:1543–1548.
   PubMed Web of Science ®Google Scholar
• Fischer M, Juremalm M, Olsson N, et al. Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer 2003;107:197–201.
   PubMed Web of Science ®Google Scholar
• Ohshima K, Karube K, Hamasaki M, et al. Differential chemokine, chemokine receptor and cytokine expression in Epstein-Barr virus-associated lymphoproliferative diseases. Leuk Lymphoma 2003;44:1367–1378.
   PubMed Web of Science ®Google Scholar
• Khan G. Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin’s lymphoma? Exp Hematol 2006;34:399–406.
   PubMed Web of Science ®Google Scholar
• Re D, Thomas RK, Behringer K, Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 2005;105:4553–4560.
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Poletto D, Nanni P, et al. Hodgkin and Reed-Sternberg cells express functional c-kit receptors and interact with primary fibroblasts from Hodgkin’s disease-involved lymph nodes through soluble and membrane-bound stem cell factor. Br J Haematol 2002;118:1055–1064.
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Poletto D, Gloghini A, et al. Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cells. Am J Pathol 2002;160:585–596.
   PubMed Web of Science ®Google Scholar
• Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor infiltrating immune cells. N Engl J Med 2004;351:2159–2169.
   PubMed Web of Science ®Google Scholar
• Burger JA, Ghia P, Rosenwald A, Caligaris-Capio F. The microenvoirement in mature B-cell malignancies: a target for new treatment strategies. Blood 2009;114:3367–3375.
   PubMed Web of Science ®Google Scholar
• Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Nat Rev Immunol 2009;9:259–270.
   PubMed Web of Science ®Google Scholar
• Lin EY, Pollard JW. Tumor associated macrophages press the angiogenic switch in breast cancer. Cancer Res 2007;67:5064–5046.
   PubMed Web of Science ®Google Scholar
• De Vita VT, Costa J. Toward a personalized treatment of Hodgkin’s disease. N Engl J Med 2010;362:942–943.
   PubMed Web of Science ®Google Scholar
• Kuppers R. The biology of Hodgkin’s lymphoma. Nat Rev Cancer 2009;9:15–27.
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Gloghini A, Pinto A, et al. The classical Hodgkin’s lymphoma microenvoirement and its role in promoting tumor growth and immune escape. J Pathol 2010;221:248–263.
   PubMed Web of Science ®Google Scholar
• Diehl V. Are macrophages the bad guys in Hodgkin lymphoma? Nature 2010;7:301–302.
   Web of Science ®Google Scholar
• Tzankov A, Matter MS, Dimhofer S. Refined prognostic role of CD68 positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology 2010;77:301–308.
   PubMed Web of Science ®Google Scholar
• Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, Nyengaard JR, d’Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin’s lymphoma. Haematologica 2011;96:269–276.
   PubMed Web of Science ®Google Scholar